HomeCompareAERI vs QYLD

AERI vs QYLD: Dividend Comparison 2026

AERI yields 13.11% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AERI wins by $22.0K in total portfolio value
10 years
AERI
AERI
● Live price
13.11%
Share price
$15.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.4K
Annual income
$2,963.65
Full AERI calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — AERI vs QYLD

📍 AERI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAERIQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AERI + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AERI pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AERI
Annual income on $10K today (after 15% tax)
$1,114.75/yr
After 10yr DRIP, annual income (after tax)
$2,519.10/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, QYLD beats the other by $2,291.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AERI + QYLD for your $10,000?

AERI: 50%QYLD: 50%
100% QYLD50/50100% AERI
Portfolio after 10yr
$36.4K
Annual income
$4,311.49/yr
Blended yield
11.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AERI right now

AERI
Analyst Ratings
15
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$15.25
0.0% upside vs current
Range: $15.25 — $15.25
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AERI buys
0
QYLD buys
0
No recent congressional trades found for AERI or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAERIQYLD
Forward yield13.11%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$47.4K$25.4K
Annual income after 10y$2,963.65$5,659.31
Total dividends collected$21.1K$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: AERI vs QYLD ($10,000, DRIP)

YearAERI PortfolioAERI Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$12,011$1,311.48$10,352$1,192.36+$1.7KAERI
2$14,324$1,472.22$10,830$1,347.57+$3.5KAERI
3$16,968$1,640.86$11,460$1,539.07+$5.5KAERI
4$19,972$1,816.53$12,275$1,777.84+$7.7KAERI
5$23,369$1,998.27$13,323$2,078.95+$10.0KAERI
6$27,190$2,185.12$14,667$2,463.34+$12.5KAERI
7$31,469$2,376.08$16,396$2,960.57+$15.1KAERI
8$36,242$2,570.14$18,631$3,612.97+$17.6KAERI
9$41,545$2,766.31$21,548$4,482.15+$20.0KAERI
10$47,417$2,963.65$25,398$5,659.31+$22.0KAERI

AERI vs QYLD: Complete Analysis 2026

AERIStock

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Full AERI Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this AERI vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AERI vs SCHDAERI vs JEPIAERI vs OAERI vs KOAERI vs MAINAERI vs XYLDAERI vs JEPQAERI vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.